Inhaled tigecycline therapy for pulmonary M. abscessus infections
吸入替加环素治疗肺部脓肿分枝杆菌感染
基本信息
- 批准号:10312329
- 负责人:
- 金额:$ 83.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-29 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAdverse effectsAerosolsAnimal ModelAntibiotic ResistanceAntibioticsBacillusBiological AvailabilityBody FluidsC57BL/6 MouseCanis familiarisChronicClarithromycinClinicClinicalClinical effectivenessColoradoComplexDepositionDoseDrug ExposureDrug KineticsDrug or chemical Tissue DistributionEpithelialExhibitsFiberFormulationFoundationsFrequenciesFutureGenus MycobacteriumGoalsGranulocyte-Macrophage Colony-Stimulating FactorHospitalsHourIn VitroInfectionInhalationInhalation Drug AdministrationInhalation TherapyInstitutesIntravenousIntravenous infusion proceduresInvestigational New Drug ApplicationKnockout MiceLightLiquid substanceLungLung AbscessLung diseasesLung infectionsMacrolidesMaximum Tolerated DoseModelingMonitorMusMycobacterium abscessusNausea and VomitingOralOrganOutcomePatientsPharmaceutical PreparationsPlasmaPowder dose formPredispositionProceduresPropertyRattusRegimenResearchResistanceRouteSafetySymptomsSystemTennesseeTestingTetracyclinesTherapeuticTherapeutic IndexTissuesToxicologyTreatment EfficacyTreatment ProtocolsUniversitiesVertebral columnWithdrawing Treatmentsanalogbacterial resistancebactericidecystic fibrosis mousecystic fibrosis patientseffective therapyefficacy testingepithelial Na+ channelflufollower of religion Jewishglycylcyclinehuman subjectimprovedin vitro Assayin vivointravenous administrationintravenous injectionliquid formulationmouse modelnon-tuberculosis mycobacteriaparticlepre-clinicalreconstitutionresistance mechanismside effectsubcutaneoussynergismtigecyclinetreatment duration
项目摘要
Summary
Mycobacterium abscessus (MAB) is a nontuberculous mycobacterium that causes chronic pulmonary infections
(pMAB) and patients with pre-existing lung disease (especially cystic fibrosis patients) have a predisposition to
pMAB. Due to MAB’s intrinsic antibiotic resistance, treatment is often complex and with low cure rates.
Tigecycline, a glycylcycline class antibiotic, demonstrates bactericidal effects against pMAB without eliciting
bacterial resistance mechanisms. For pMAB treatment, patients receive twice daily intravenous administration
of tigecycline during at least one month resulting in significant side effects and many patients withdraw from
treatment. Tigecycline has the potential to qualify as the first-line agent during therapy for pMAB and the
backbone for new combination regimens but to achieve its fullest therapeutic potential, we need to improve
tigecyclines ratio between efficacy and safety/tolerability, i.e. its therapeutic index. One approach to address this
challenge is to develop inhalational formulations of tigecycline that are easy to administer and are well
tolerated. In preliminary studies, GM-CSF KO mice with pMAB were treated by intrapulmonary aerosols of
tigecycline for 28 days. The pulmonary bacterial burden after full treatment duration showed that inhaled
tigecycline has high, dose-dependent efficacy, and is well tolerated. Here we hypothesize that aerosol delivery
of tigecycline is a viable therapeutic approach for pMAB. In Aim 1, to avoid the tigecycline requirements for
reconstitution, we will develop a dry powder formulation of tigecycline with well characterized aerodynamic
properties suitable for inhalation. Aim 2 will study the relationship between dose, dosing regimen and resulting
exposure of aerosols of tigecycline in different body fluids, organs and tissues. In particular, we will study the
dose-exposure relationship of inhaled versus intravenous tigecycline and its availability in plasma, lung,
abscesses and epithelial lining fluid. In Aim 3, we propose to test the efficacy, dose, dosing frequency, and
duration of inhaled tigecycline against pMAB using animal models. We propose using first the GM-CSF KO
murine model, subsequently, we will test the best regimen in b-ENac Tg mice with pMAB infection, as a
representative model for cystic fibrosis patients. The best regimen will be validated in mice infected with selected
clinical isolates from MAB clones 1 and 2 and isolates obtained from cystic fibrosis patients. Aim 4 will
determine efficacy of inhaled tigecycline in multidrug therapies. Mice with pMAB as in Aim 3 (with strain
#21 or clinical isolates) will be treated with binary or ternary combinations of inhaled tigecycline and
clarithromycin (oral), clofazimine (oral), bedaquiline (oral). These studies will be performed by a consortium of
experts located at Colorado State University, University of Tennessee, Research Triangle Institute and National
Jewish Hospital. Working together, we aim to provide an inhalational therapy regimen of tigecycline with well-
defined aerodynamic and PK properties and well characterized in vivo efficacy for future preclinical toxicology
studies in larger animal models, IND application, and ultimately administration to patients.
摘要
脓肿分枝杆菌(MAB)是一种引起慢性肺部感染的非结核分枝杆菌。
(PMAb)和既有肺部疾病的患者(尤其是囊性纤维化患者)容易发生
PMAB。由于MAB固有的抗生素耐药性,治疗往往复杂且治愈率低。
替加环素是一种甘环素类抗生素,对pMAb有杀菌作用,但不诱导
细菌耐药机制。对于pMAb治疗,患者每天接受两次静脉注射
在至少一个月内服用替加环素会导致严重的副作用,许多患者退出
治疗。替格环素有可能成为pMAb和pMAB治疗的一线药物
新联合疗法的主心骨,但要充分发挥其治疗潜力,我们需要改进
替加环素类药物疗效与安全性/耐受性的比率,即其治疗指数。解决这个问题的一种方法
面临的挑战是开发易于管理且效果良好的替吉环素吸入性制剂
被容忍了。在初步研究中,用pMAb感染的GM-CSF KO小鼠被肺内雾化吸入
替加环素28天。治疗满疗程后的肺部细菌负荷显示吸入
替格环素的疗效高,且具有剂量依赖性,且耐受性良好。在这里我们假设气雾剂的传递
替加环素是治疗pMAB的一种可行的方法。在目标1中,为了避免对替吉环素的要求
重组,我们将开发一种具有良好空气动力学特性的替加环素干粉配方
适合吸入的特性。目标2将研究剂量、给药方案和结果之间的关系
替加环素气雾剂在不同体液、器官和组织中的暴露。我们会特别研究
替吉环素吸入与静脉给药的剂量-暴露关系及其在血浆、肺中的利用度
脓肿和上皮性衬里液体。在目标3中,我们建议测试疗效、剂量、给药频率和
吸入替吉环素抗pMAb动物模型的持续时间。我们建议首先使用GM-CSF KO
小鼠模型,随后,我们将在pMAb感染的b-enac转基因小鼠中测试最佳方案,作为
囊性纤维化患者的代表性模型。最佳方案将在感染选定病毒的小鼠身上得到验证
单抗克隆1和2的临床分离株以及囊性纤维化患者的分离株。目标4将
确定吸入替吉环素在多药治疗中的疗效。与Aim 3中相同的pMAb小鼠(带品系
#21或临床分离株)将使用吸入替吉环素和
克拉霉素(口服)、氯法齐明(口服)、贝达奎兰(口服)。这些研究将由一个财团进行
科罗拉多州立大学、田纳西大学、三角研究所和国立大学的专家
犹太医院。通过合作,我们的目标是提供一种替环素吸入疗法,该疗法具有良好的
明确的空气动力学和PK特性,以及对未来临床前毒理学的体内疗效的良好表征
在更大的动物模型中的研究,IND的应用,以及最终对患者的管理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mercedes Gonzalez-Juarrero其他文献
Mercedes Gonzalez-Juarrero的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mercedes Gonzalez-Juarrero', 18)}}的其他基金
Inhaled tigecycline therapy for pulmonary M. abscessus infections
吸入替加环素治疗肺部脓肿分枝杆菌感染
- 批准号:
10437923 - 财政年份:2021
- 资助金额:
$ 83.64万 - 项目类别:
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis
结核分枝杆菌多糖的剪裁修饰
- 批准号:
10490882 - 财政年份:2021
- 资助金额:
$ 83.64万 - 项目类别:
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis
结核分枝杆菌多糖的剪裁修饰
- 批准号:
10685409 - 财政年份:2021
- 资助金额:
$ 83.64万 - 项目类别:
Tailoring modifications of polysaccharides in Mycobacterium tuberculosis
结核分枝杆菌多糖的剪裁修饰
- 批准号:
10387219 - 财政年份:2021
- 资助金额:
$ 83.64万 - 项目类别:
Inhaled tigecycline therapy for pulmonary M. abscessus infections
吸入替加环素治疗肺部脓肿分枝杆菌感染
- 批准号:
10626051 - 财政年份:2021
- 资助金额:
$ 83.64万 - 项目类别:
Vectra Polaris microscope imaging system
Vectra Polaris 显微镜成像系统
- 批准号:
10175807 - 财政年份:2021
- 资助金额:
$ 83.64万 - 项目类别:
Minipigs as animal model for infant TB and vaccine efficacy
小型猪作为婴儿结核病和疫苗功效的动物模型
- 批准号:
8810222 - 财政年份:2014
- 资助金额:
$ 83.64万 - 项目类别:
siRNA-nanoparticles host targeted immunotherapy for tuberculosis
siRNA 纳米颗粒作为结核病靶向免疫疗法的宿主
- 批准号:
8638299 - 财政年份:2014
- 资助金额:
$ 83.64万 - 项目类别:
Minipigs as animal model for infant TB and vaccine efficacy
小型猪作为婴儿结核病和疫苗功效的动物模型
- 批准号:
8684285 - 财政年份:2014
- 资助金额:
$ 83.64万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 83.64万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 83.64万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 83.64万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 83.64万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 83.64万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 83.64万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 83.64万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 83.64万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 83.64万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 83.64万 - 项目类别:
Research Grant